Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Multiple Myeloma 4Hematologic Neoplasms 4Carcinoma, Renal Cell 4Breast Neoplasms 4Prostatic Neoplasms 3Neuroendocrine Tumors 3Urothelial Cancer 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Adenoma, Islet Cell 2von Hippel-Lindau Disease 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Stomach Neoplasms 1

Interventions

ibrutinib 1fludarabine phosphate 1Rituximab 1Pharmacogenomic Testing 1Cyclophosphamide 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Anemia × 30 days × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡